Notation to File

LIGHTSHIP

LIGHTSHIP INC.

RE: 88264600 LIGHTSHIP     Dear Ms. Cantone-   We are amenable to entry of an Examiner’s Amendment to clarify the Class 42 description, as proposed in your November 11, 2019 message below.  Please proceed with entry of an Examiner’s Amendment and approval of the application for publication. Feel free to contact me if any further information is needed.   Respectfully submitted, /lcs/     LINDSAY COHEN SCHNEIDER CounselBRYAN CAVE LEIGHTON PAISNER LLP - St. Louis, MO USA lindsay.schneider@bclplaw.com T: +1 314 259 2481   Docketing: BCIPdocketing@bclplaw.com

NOTE TO THE FILE


SERIAL NUMBER:            88264600

DATE:                                11/12/2019

NAME:                               kcantone

NOTE:         

Searched:                                                             
     Google                            
     Lexis/Nexis                       
     OneLook
     Wikipedia
     Acronym Finder                         Protest evidence reviewed
     Other:

Checked:                                                             
     Geographic significance          
     Surname                          
     Translation
     ID with ID/CLASS mailbox

     Checked list of approved Canadian attorneys and agents

Discussed file with
Attorney/Applicant via:
        phone                               Left message with
        email                               Attorney/Applicant

     Requested Law Library search           Issued Examiner’s Amendment
     for:                                   and entered changes in TRADEUPS

        PRINT        DO NOT PRINT           Added design code in TRADEUPS
     Description of the mark
     Translation statement                  Re-imaged standard character
                                            drawing
     Negative translation statement             
     Consent of living individual           Contacted TM MADRID ID/CLASS
                                            about misclassified definite ID
     Changed TRADEUPS to:

     OTHER:

 

 

From: Schneider, Lindsay <lindsay.schneider@bclplaw.com>
Sent: Tuesday, November 12, 2019 11:53 AM
To: Cantone, Keri <Keri.Cantone@USPTO.GOV>
Cc: Bryan Cave IP Docketing <bcipdocketing@bclplaw.com>
Subject: RE: 88264600 LIGHTSHIP

 

 

Dear Ms. Cantone-

 

We are amenable to entry of an Examiner’s Amendment to clarify the Class 42 description, as proposed in your November 11, 2019 message below.  Please proceed with entry of an Examiner’s Amendment and approval of the application for publication. Feel free to contact me if any further information is needed.

 

Respectfully submitted,

/lcs/

 

 

LINDSAY COHEN SCHNEIDER
Counsel
BRYAN CAVE LEIGHTON PAISNER LLP - St. Louis, MO USA
lindsay.schneider@bclplaw.com

T: +1 314 259 2481  


Docketing: BCIPdocketing@bclplaw.com

 

From: Cantone, Keri [mailto:Keri.Cantone@USPTO.GOV]
Sent: Monday, November 11, 2019 6:03 PM
To: Schneider, Lindsay
Subject: 88264600 LIGHTSHIP

 

Ms. Schneider:

 

The above has come back to me for correction of a portion of the Class 42 identification.  The following clarification is required:

 

Class 42: Conducting clinical trials for others; Medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical and non-clinical trials and studies on pharmaceuticals and medical devices for others; Scientific consulting and research services for others in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Virtual consulting services regarding medical and scientific research in relation to clinical trials only; Design and development of software for use in conducting research in clinical and non-clinical pharmaceutical and medical device and development studies; Software as a service (SAAS) services featuring software for use in a telemedicine platform for use in clinical research; Platform as a service (PAAS) featuring computer software platforms for the purposes of exchanging data between the medical care providers, researchers, and patients; Providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; Providing online non-downloadable software for tracking, monitoring, analyzing, generating and reporting patient information and healthcare statistics in clinical and non-clinical pharmaceutical and medical device and development studies

 

I can be reached via email, or a the number below.

 

Sincerely,

 

Keri-Marie Cantone

Trademark Examining Attorney- Law Office 104

United States Patent & Trademark Office

(571) 272-6069

 

 

This electronic message is from a law firm. It may contain confidential or privileged information. If you received this transmission in error, please reply to the sender to advise of the error and delete this transmission and any attachments.

We may monitor and record electronic communications in accordance with applicable laws and regulations. Where appropriate we may also share certain information you give us with our other offices (including in other countries) and select third parties. For further information (including details of your privacy rights and how to exercise


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed